Czech National Bank Raises Stock Holdings in Gilead Sciences, Inc. $GILD

Czech National Bank increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.6% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 353,398 shares of the biopharmaceutical company’s stock after purchasing an additional 15,504 shares during the period. Czech National Bank’s holdings in Gilead Sciences were worth $44,648,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in Gilead Sciences in the 4th quarter valued at about $2,617,152,000. Boston Partners purchased a new stake in Gilead Sciences during the 4th quarter worth approximately $517,808,000. Massachusetts Financial Services Co. MA boosted its position in Gilead Sciences by 3,763.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock valued at $518,368,000 after buying an additional 4,113,999 shares during the period. Bank of America Corp DE increased its position in shares of Gilead Sciences by 15.2% during the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after acquiring an additional 3,046,688 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Gilead Sciences by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after acquiring an additional 2,113,692 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Trading Down 0.7%

NASDAQ:GILD opened at $130.86 on Friday. Gilead Sciences, Inc. has a 1 year low of $108.46 and a 1 year high of $157.29. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.14. The stock has a fifty day moving average price of $129.43 and a two-hundred day moving average price of $136.22. The stock has a market capitalization of $162.47 billion, a price-to-earnings ratio of -49.01 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same quarter last year, the business earned $2.01 earnings per share. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.65 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the sale, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. This represents a 1.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the completion of the sale, the insider directly owned 124,234 shares in the company, valued at $15,395,077.28. This trade represents a 2.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 82,000 shares of company stock worth $10,641,790. 0.30% of the stock is owned by corporate insiders.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported second-quarter revenue of $7.8 billion, above the roughly $7.4 billion consensus estimate. Product sales excluding Veklury rose 10% year over year to $7.6 billion, led by HIV medicines and Trodelvy. GILD Q2 Earnings Beat
• Positive Sentiment: Management raised its HIV growth outlook to 9%–10% and highlighted rapid adoption of Yeztugo, its HIV prevention treatment. PrEP sales reportedly doubled to approximately $1 billion, supporting the view that HIV remains Gilead’s primary growth engine. Q2 Earnings Call Highlights
• Positive Sentiment: Several analysts remain constructive: Cantor Fitzgerald reiterated an Overweight rating with a $155 target, while Needham reaffirmed Buy with a $170 target. Gilead also declared its $0.82 quarterly dividend, providing continued income support.
• Neutral Sentiment: The quarter was described as operationally strong, but reported earnings guidance remains negative because of acquisition-related charges and elevated research spending. The company’s 2026 base-business sales outlook is approximately $29.8 billion–$30.1 billion.
• Negative Sentiment: Gilead posted a $6.75 per-share quarterly loss versus $2.01 of earnings a year earlier. The loss was driven largely by acquisition-related costs, increasing concern about near-term profitability despite the revenue beat. Strong Quarter Hidden Behind Ugly Earnings
• Negative Sentiment: MSD and Gilead discontinued a Phase III Trodelvy-Keytruda study after lacklustre interim data. The failure weakens expectations for expanding Trodelvy’s use in combination therapy and adds uncertainty to Gilead’s oncology growth strategy. Trodelvy-Keytruda Study Discontinued
• Negative Sentiment: Veklury sales continued to decline sharply, while AIDS Healthcare Foundation criticized Gilead’s HIV pricing and access policies. The controversy could create reputational or longer-term market-access risks. CEO Daniel O’Day’s planned sale of 15,000 shares was a minor additional negative signal.

Wall Street Analyst Weigh In

GILD has been the topic of a number of recent research reports. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research note on Wednesday, May 20th. Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Daiwa Securities Group reduced their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, May 19th. Barclays reduced their price target on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 29th. Finally, Citigroup raised their price target on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Twenty-five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $158.04.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.